Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole with or without synbiotic for infant reflux
IRCT20090808002306N12Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of esomeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Change in clinical reflux symptoms based on I-GERQ score, Frequency of reflux episodes and 1 more. Started Jun 2026; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on IRCT20090808002306N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090808002306N12.